Table 3 GRADE evidence profile of glucagon-like peptide-1 receptor agonists and risk of heart failure in type 2 diabetes
Quality assessment | Summary of findings | Quality of evidence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Study event rates | Relative risk (95 % CI) | Anticipated absolute effects (5-year time frame) | |||||||||
No of participants (studies) Follow-up time | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | With control | With GLP-1 agonists | Risk with control | Risk difference with GLP-1 agonists (95 % CI) | ||
Heart failure | |||||||||||
 11758  (20)  16-164 weeks | Serious limitation due to risk of biasa | No serious limitations | No serious limitations | Serious limitation, confidence interval includes important benefit and harm | Undetected | 19/4317 (0.44 %) | 17/7441 (0.23 %) | OR 0.62 (0.31 to 1.22) | 50 per 1000b | 19 fewer per 1000 (34 fewer to 11 more) | ⊕ ⊕ ΟΟ Low due to risk of bias and imprecision |
Hospitalization for heart failure | |||||||||||
 6068  (1)  2.1 years | No serious limitations | No serious limitations | No serious limitations | Serious limitation, confidence interval includes important benefit and harm | Undetected | 127/3034 4.2 % | 122/3034 4 % | HR 0.96 (0.75 to 1.23) | 100 per 1000c | 4 fewer per 1000 (25 fewer to 23 more) | ⊕ ⊕ ⊕Ο Moderate due to imprecision |